Preventable Vaccines Market Size, Share, Trends, Growth Outlook

Preventable Vaccines Market is estimated to increase at a growth rate of 2.8% CAGR over the forecast period from 2024 to 2030.

The global Preventable Vaccines Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others), By Indication (Pneumococcal Disease, Influenza, Polio, Hepatitis, Others), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Homecare, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy).

An Introduction to Preventable Vaccines Market in 2024

The Preventable Vaccines Market in 2024 addresses the global demand for vaccines targeting infectious diseases that are preventable through immunization, offering protection against a wide range of pathogens such as bacteria, viruses, and parasites. Preventable vaccines encompass routine childhood vaccines, adult immunizations, and travel vaccines recommended by public health authorities and international organizations to prevent vaccine-preventable diseases (VPDs) such as measles, influenza, polio, hepatitis, and human papillomavirus (HPV). With vaccination being one of the most cost-effective public health interventions, the preventable vaccines market witnesses sustained demand and innovation, driven by factors such as expanding vaccination programs, disease eradication initiatives, and advancements in vaccine technology and delivery platforms. Moreover, as stakeholders in global health, immunization advocacy, and pandemic preparedness collaborate to improve vaccine access, vaccine equity, and vaccine confidence worldwide, the preventable vaccines market plays a vital role in reducing the burden of infectious diseases, preventing outbreaks, and promoting population health across all age groups and demographics.

Preventable Vaccines Market Competitive Landscape

The global Preventable Vaccines Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Preventable Vaccines Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Preventable Vaccines Industry include- Bharat Biotech, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, EMERGENT, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co. Inc, Mylan N.V., Novartis AG, Pfizer Inc, Sanofi SA, Serum Institute of India Pvt. Ltd.

Preventable Vaccines Market Trend: Focus on Preventive Healthcare Strategies

The market trend for Preventable Vaccines is a growing focus on preventive healthcare strategies. With increasing awareness of the importance of vaccination in preventing infectious diseases, there is a shift towards proactive approaches to healthcare. Governments, healthcare organizations, and individuals are emphasizing the importance of vaccination campaigns, routine immunization schedules, and public health initiatives to reduce the burden of preventable diseases. This trend is driving the demand for a wide range of preventive vaccines targeting various infectious pathogens, including viruses, bacteria, and other pathogens. Additionally, advancements in vaccine technology, such as the development of novel vaccine platforms, adjuvants, and delivery systems, are further fueling the growth of the preventable vaccines market.

Preventable Vaccines Market Driver: Rising Incidence of Infectious Diseases and Outbreaks

The market driver for Preventable Vaccines is the rising incidence of infectious diseases and outbreaks globally. Despite significant progress in vaccination efforts, infectious diseases continue to pose significant public health challenges, leading to outbreaks, epidemics, and pandemics. Factors such as globalization, urbanization, population growth, antimicrobial resistance, and climate change contribute to the emergence and spread of infectious pathogens. Consequently, there is a growing need for effective preventive measures, including vaccination, to control the transmission of infectious diseases, protect vulnerable populations, and prevent healthcare crises. The increasing incidence of vaccine-preventable diseases, such as measles, influenza, pneumococcal disease, and human papillomavirus (HPV) infection, underscores the critical role of vaccination in maintaining public health and reducing healthcare costs.

Preventable Vaccines Market Opportunity: Expansion of Vaccination Programs and Access

The Market Opportunity for Preventable Vaccines lies in the expansion of vaccination programs and access to underserved populations. Despite the availability of vaccines, disparities in vaccination coverage persist, particularly in low- and middle-income countries and marginalized communities. To address this gap, there is a growing focus on improving vaccine accessibility, affordability, and delivery infrastructure through various initiatives, including immunization campaigns, public-private partnerships, and vaccine donation programs. Furthermore, advancements in vaccine distribution logistics, cold chain management, and needle-free vaccine delivery technologies are enhancing the reach and effectiveness of vaccination programs, especially in remote and resource-limited settings. By leveraging these opportunities, stakeholders in the preventable vaccines market can maximize the impact of vaccination efforts, achieve herd immunity, and contribute to global health security and equity.

Preventable Vaccines Market Share Analysis: Influenza is the fastest growing market segment over the forecast period to 2030

Preventable vaccines for influenza emerge as the fastest-growing segment in the preventable vaccines market. This growth is propelled by several factors, including the seasonal nature of influenza outbreaks, the continuous evolution of influenza viruses, and the global public health focus on influenza prevention and control. Influenza vaccines are crucial in reducing the burden of influenza-related illness, hospitalizations, and mortality, particularly among high-risk populations such as the elderly, young children, pregnant women, and individuals with underlying health conditions. With the increasing awareness of influenza as a significant respiratory infection and the importance of vaccination in preventing its spread, there is a growing demand for influenza vaccines across various end-users, including hospitals, homecare settings, specialty clinics, and others. Additionally, advancements in vaccine manufacturing technologies, such as cell-based and recombinant influenza vaccine production, contribute to the availability and accessibility of influenza vaccines, further driving market growth. As healthcare systems prioritize influenza vaccination campaigns and implement strategies to enhance vaccine coverage rates, the market for preventable vaccines for influenza is expected to witness significant expansion, playing a pivotal role in global influenza prevention efforts and public health initiatives.

Preventable Vaccines Market Segmentation

By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Preventable Vaccines Companies

Bharat Biotech
Boehringer Ingelheim International GmbH.
Bristol-Myers Squibb Company
EMERGENT
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Merck & Co. Inc
Mylan N.V.
Novartis AG
Pfizer Inc
Sanofi SA
Serum Institute of India Pvt. Ltd
* List not Exhaustive

Reasons to Buy the Preventable Vaccines Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Preventable Vaccines Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Preventable Vaccines Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Preventable Vaccines Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Preventable Vaccines Market Size Outlook, $ Million, 2021 to 2030
3.2 Preventable Vaccines Market Outlook by Type, $ Million, 2021 to 2030
3.3 Preventable Vaccines Market Outlook by Product, $ Million, 2021 to 2030
3.4 Preventable Vaccines Market Outlook by Application, $ Million, 2021 to 2030
3.5 Preventable Vaccines Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Preventable Vaccines Industry
4.2 Key Market Trends in Preventable Vaccines Industry
4.3 Potential Opportunities in Preventable Vaccines Industry
4.4 Key Challenges in Preventable Vaccines Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Preventable Vaccines Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Preventable Vaccines Market Outlook by Segments
7.1 Preventable Vaccines Market Outlook by Segments, $ Million, 2021- 2030
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
8 North America Preventable Vaccines Market Analysis and Outlook To 2030
8.1 Introduction to North America Preventable Vaccines Markets in 2024
8.2 North America Preventable Vaccines Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Preventable Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
9 Europe Preventable Vaccines Market Analysis and Outlook To 2030
9.1 Introduction to Europe Preventable Vaccines Markets in 2024
9.2 Europe Preventable Vaccines Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Preventable Vaccines Market Size Outlook by Segments, 2021-2030
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
10 Asia Pacific Preventable Vaccines Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Preventable Vaccines Markets in 2024
10.2 Asia Pacific Preventable Vaccines Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Preventable Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
11 South America Preventable Vaccines Market Analysis and Outlook To 2030
11.1 Introduction to South America Preventable Vaccines Markets in 2024
11.2 South America Preventable Vaccines Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Preventable Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
12 Middle East and Africa Preventable Vaccines Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Preventable Vaccines Markets in 2024
12.2 Middle East and Africa Preventable Vaccines Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Preventable Vaccines Market size Outlook by Segments, 2021-2030
By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Bharat Biotech
Boehringer Ingelheim International GmbH.
Bristol-Myers Squibb Company
EMERGENT
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Merck & Co. Inc
Mylan N.V.
Novartis AG
Pfizer Inc
Sanofi SA
Serum Institute of India Pvt. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Technology
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Others
By Indication
Pneumococcal Disease
Influenza
Polio
Hepatitis
Others
By Route of Administration
Oral
Parenteral
By End-User
Hospitals
Homecare
Specialty Clinics
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy